For decades, metformin has attracted intense interest as a potential longevity-extending compound beyond its glucose-lowering role — a hypothesis now being formally tested in large trials like TAME. The DEMFOS trial adds a clinically important counterpoint: when it comes to preserving or improving physical function in older adults managing obesity through structured lifestyle intervention, metformin appears to offer nothing extra.
The DEMFOS randomised controlled trial enrolled older adults with obesity who were already enrolled in an intensive lifestyle intervention program. Participants were randomised to receive metformin or placebo on top of this structured lifestyle protocol. The primary outcome — physical function, likely measured through composite assessments such as gait speed, chair-stand performance, or validated functional scales — showed no statistically significant advantage in the metformin arm. The trial's conclusion was pointed: lifestyle-based strategies alone appear sufficient for functional improvement in this population, and metformin confers no additive benefit in this context.
This finding carries real weight in the longevity research landscape. Metformin's proposed mechanisms — AMPK activation, mTOR suppression, mitochondrial complex I inhibition — theoretically align with preservation of muscle and metabolic function in aging. Yet mechanistic plausibility has consistently outrun clinical evidence. Notably, some prior research has raised concerns that metformin may actually blunt exercise-induced adaptations in older adults, including attenuating gains in insulin sensitivity and aerobic capacity. DEMFOS doesn't confirm that attenuation, but it does reinforce the absence of synergy. The limitation worth flagging is that this population was already receiving intensive lifestyle support — a high baseline intervention that may have created a ceiling effect, leaving little room for pharmacological augmentation. Whether metformin benefits functionally sedentary or lower-intensity intervention groups remains an open question. Overall, this is a confirmatory and sobering finding for metformin's functional longevity narrative, reinforcing that exercise and diet remain the most evidence-backed tools for healthy aging.
